Zobrazeno 1 - 10
of 106
pro vyhledávání: '"ATTR-CM"'
Autor:
Eugenia Volpentesta, Mounira Kharoubi, Cristiano Donadio, Kahina Rebiai, Pascale Fanen, Benoit Funalot, Thierry Gendre, Vincent Audard, Florence Canoui‐Poitrine, Emmanuel Itti, Emmanuel Teiger, Violaine Planté‐Bordeneuve, Silvia Oghina, Denis Tixier, Sophie Mallet, Amaury Broussier, Thibaud Damy, Amira Zaroui
Publikováno v:
ESC Heart Failure, Vol 11, Iss 6, Pp 3814-3832 (2024)
Abstract Aims Transthyretin cardiac amyloidosis (ATTR‐CM) may be an underestimated cause of heart failure among geriatric patients and represent a unique phenotype and prognostic profile. Methods and results This retrospective, observational, cohor
Externí odkaz:
https://doaj.org/article/4c1079661c08452fbc46f6c108c58253
Autor:
Eman S. AL_Akhali, Sultan A. Alshoabi, Abdullgabbar M. Hamid, Kamal D. Alsultan, Awatif M. Omer, Mohammed A. Alhammadi
Publikováno v:
Radiology Case Reports, Vol 19, Iss 11, Pp 4730-4735 (2024)
Cardiac amyloidosis is indeed a condition characterized by the deposition of amyloid proteins in the myocardium, leading to thickening and stiffening of the heart muscle. These abnormal protein deposits can interfere with the heart's normal functioni
Externí odkaz:
https://doaj.org/article/0b11ea2ef16f455b84483496952c5e3c
Autor:
Takao Kato, Monica Ines, Masatoshi Minamisawa, Darrin Benjumea, Denis Keohane, Jose Alvir, Ruth Kim, Yong Chen, Telma Peixoto, Matthew Kent, Jenifer Wogen, Tomonori Ishii, Aaron Crowley, Toshiya Sugino, Yasuhiro Izumiya
Publikováno v:
ESC Heart Failure, Vol 11, Iss 5, Pp 2881-2888 (2024)
Abstract Aims This study aimed to describe baseline characteristics and adherence among patients with transthyretin amyloid cardiomyopathy (ATTR‐CM) treated with tafamidis (VYNDAQEL®) in Japan using the Japanese Medical Data Vision (MDV) database.
Externí odkaz:
https://doaj.org/article/6ac02c28c3084c10b32d2e82c4af7ca5
Autor:
Ikponmwosa Jude Ogieuhi, Oshomoh Mark-Anthony Ugiomoh, Kudzaishe Muzofa, Kristen Callender, Johnson David Ayodeji, Nnokam Prayer Nnekachi, Barkavi Thiyagarajan, Emmanuel Obokhai Uduigwome, Abhay Kapoor, Moses Chukwuebuka Odoeke, Reem Gamaleldin Hassan Mohamed, Courage Idahor
Publikováno v:
The Egyptian Heart Journal, Vol 76, Iss 1, Pp 1-17 (2024)
Abstract Background Amyloidosis is a heterogeneous group of disorders caused by the extracellular deposition of insoluble misfolded proteins, leading to end-organ damage. Transthyretin amyloid cardiomyopathy (ATTR-CM) is a subtype in which a protein
Externí odkaz:
https://doaj.org/article/a8c54cc47ca6454085b20d4f33006a0e
Publikováno v:
Cardiology and Therapy, Vol 13, Iss 2, Pp 369-378 (2024)
Abstract Introduction Tafamidis is the first drug approved by the European Commission for the treatment of wild-type or hereditary transthyretin amyloid cardiomyopathy (ATTR-CM) in adults to reduce cardiovascular mortality and cardiovascular-related
Externí odkaz:
https://doaj.org/article/b41fef91209b4a70bfc1a7d61417730e
Autor:
Margrethe Flesvig Holt, August Flø, Håvard Ravnestad, Vilde Bjørnø, Lars Gullestad, Arne K. Andreassen, Kaspar Broch, Einar Gude
Publikováno v:
ESC Heart Failure, Vol 11, Iss 2, Pp 1263-1268 (2024)
Abstract Aims Our aim was to investigate haemodynamics at rest and during exercise in patients with transthyretin cardiomyopathy (ATTR‐CM) in light of the 2022 European Society of Cardiology (ESC) and European Respiratory Society (ERS) guidelines o
Externí odkaz:
https://doaj.org/article/51a23a00f280434e945ff1535a01b97c
Autor:
Per Eldhagen, Jukka Lehtonen, Einar Gude, Finn Gustafsson, Anne Bagger‐Bahnsen, Merja Vakevainen, Trine Pilgaard, Dorte Wedell‐Wedellsborg, Steen Hvitfeldt Poulsen, Nordic PROACT study group
Publikováno v:
ESC Heart Failure, Vol 10, Iss 3, Pp 1871-1882 (2023)
Abstract Aims Transthyretin amyloid cardiomyopathy (ATTR CM) is a progressive and severe heart disease with physical and psychological implications. The Nordic PROACT study was conducted to investigate the health‐related quality of life (HRQoL) in
Externí odkaz:
https://doaj.org/article/22146d277fc24277a00788bc6a66e10f
Autor:
Frida Hjalte, Jenny M. Norlin, Linda Alverbäck-Labberton, Katarina Johansson, Gerhard Wikström, Per Eldhagen
Publikováno v:
Annals of Medicine, Vol 55, Iss 2 (2023)
AbstractAims To estimate healthcare resource use and direct healthcare costs of Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in Sweden over 12 months across severity stages as defined by the New York Heart Association (NYHA). Secondary to investiga
Externí odkaz:
https://doaj.org/article/53b25cafcea249289d53af381e026c49
Autor:
Jagdish Chander Mohan, Jamshed Dalal, Vijay Kumar Chopra, Calambur Narasimhan, Prafulla Kerkar, Abraham Oomman, Saumitra Ray Fcsi, Anshu Rajnish Sharma, Pankaj Dougall, Shelley Simon, Atul Verma Drm, Vivek Radhakrishnan
Publikováno v:
Indian Heart Journal, Vol 74, Iss 6, Pp 441-449 (2022)
Transthyretin cardiac amyloidosis (ATTR-CM) is a rare and under-recognized disorder characterized by the aggregation of transthyretin-derived insoluble amyloid fibrils in the myocardium. Heterogeneity of symptoms at presentation, makes its diagnosis
Externí odkaz:
https://doaj.org/article/6c32440f26914cd3abf3eb45ca5a66ef
Autor:
Abdullah Alqarni, Ahmed Aljizeeri, Aquib Mohammadidrees Bakhsh, Hossam Ahmed Maher El-Zeftawy, Hussein R. Farghaly, Mukhtar Ahmed M. Alqadhi, Mushref Algarni, Zain Mohammed Asiri, Ahmed Osman, Haya Haddadin, Islam Alayary, Mouaz H. Al-Mallah
Publikováno v:
Diagnostics, Vol 14, Iss 2, p 212 (2024)
Transthyretin amyloid cardiomyopathy (ATTR-CM) is a complex and serious form of heart failure caused by the accumulation of transthyretin amyloid protein in the heart muscle. Variable symptoms of ATTR-CM can lead to a delayed diagnosis. Recognizing t
Externí odkaz:
https://doaj.org/article/426693427c3148219ff4d3ef9ea582f6